Genmab A/S(DE:GE9)
€479.30+-10.30 (+1.20%)
DE:GE9
Genmab A/S stock forecast
€479.30
At close:+-10.30 (+1.20%)
Genmab A/S (GE9) Stock Forecast & Price Target
15 Followers
GE9 Analyst Ratings
Strong Buy
6Buy0Hold0Sell
Based on 6 analysts giving stock ratings to Genmab A/S in the past 3 months
GE9 Stock 12 Month Forecast
Average Price Target
EUR 502.76▲(4.89% Upside)Based on 6 Wall Street analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is EUR 502.76 with a high forecast of EUR 601.97 and a low forecast of EUR 334.43. The average price target represents a 4.89% change from the last price of EUR 479.30.
Past 12 Months12 Month ForecastJan2026Oct2026
HighEUR 601.97
AverageEUR 502.76
LowEUR 334.43
Highest Price TargetHighestEUR 601.97Average Price TargetEUR 502.76Lowest Price TargetLowestEUR 334.43
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| James Gordon CFA | Barclays | EUR 601.97 | buy | 25.59%Upside | Reiterated | 11/09/26 | ||
| Charlie Haywood | Bank of America Securities | EUR 428.07→EUR 588.60 | buy | 22.80%Upside | Reiterated | 11/02/26 | ||
| Rajan Sharma | Goldman Sachs | EUR 321.05→EUR 595.29 | buy | 24.20%Upside | Reiterated | 10/29/26 | ||
| Benjamin Jackson CFA | Jefferies | EUR 387.94→EUR 428.07 | buy | -10.69%Downside | Reiterated | 10/29/26 | ||
| Zain Ebrahim | J.P. Morgan | EUR 274.23→EUR 468.20 | buy | -2.32%Downside | Upgraded | 10/26/26 | ||
| Emmanuel Papadakis | Deutsche Bank | EUR 300.99→EUR 334.43 | buy | -30.23%Downside | Reiterated | 09/01/26 | ||
| Xian Deng | UBS | EUR 361.18 | buy | -24.64%Downside | Reiterated | 08/07/26 | ||
| Jon Berggren | Kepler Capital | EUR 280.92 | hold | -41.39%Downside | Reiterated | 05/07/26 | ||
| Victor Floc'h | Exane BNP Paribas | EUR 321.05 | buy | -33.02%Downside | Upgraded | 04/22/26 | ||
| Justin Smith | Bernstein | EUR 135.78→EUR 187.28 | sell | -60.93%Downside | Reiterated | 02/23/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| James Gordon CFABarclays | BuyReiteratedEUR 601.97 | 11/09/26 | 25.59%Upside | ||
| Charlie HaywoodBank of America Securities | BuyReiteratedEUR 428.07→EUR 588.60 | 11/02/26 | 22.80%Upside | ||
| Rajan SharmaGoldman Sachs | BuyReiteratedEUR 321.05→EUR 595.29 | 10/29/26 | 24.20%Upside | ||
| Benjamin Jackson CFAJefferies | BuyReiteratedEUR 387.94→EUR 428.07 | 10/29/26 | -10.69%Downside | ||
| Zain EbrahimJ.P. Morgan | BuyUpgradedEUR 274.23→EUR 468.20 | 10/26/26 | -2.32%Downside | ||
| Emmanuel PapadakisDeutsche Bank | BuyReiteratedEUR 300.99→EUR 334.43 | 09/01/26 | -30.23%Downside | ||
| Xian DengUBS | BuyReiteratedEUR 361.18 | 08/07/26 | -24.64%Downside | ||
| Jon BerggrenKepler Capital | HoldReiteratedEUR 280.92 | 05/07/26 | -41.39%Downside | ||
| Victor Floc'hExane BNP Paribas | BuyUpgradedEUR 321.05 | 04/22/26 | -33.02%Downside | ||
| Justin SmithBernstein | SellReiteratedEUR 135.78→EUR 187.28 | 02/23/26 | -60.93%Downside |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering Genmab A/S
3 Months
Success Rate6/10 ratings generated profit
60%
Average Return
+21.39%
Copying James Gordon CFA's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +21.39% per trade.
1 Year
Success Rate8/10 ratings generated profit
80%
Average Return
+63.24%
Copying James Gordon CFA's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +63.24% per trade.
2 Years
Success Rate9/10 ratings generated profit
90%
Average Return
+66.54%
Copying James Gordon CFA's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +66.54% per trade.
GE9 Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 9 | 6 | 9 | 20 | 20 |
| Hold | 1 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 10 | 6 | 9 | 20 | 20 |
In the current month, GE9 has received 20 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GE9 average Analyst price target in the past 3 months is 502.76.
GE9 Financial Forecast
HighEUR 3.40
ConsensusEUR 2.02
LowEUR 0.61
GE9 Earnings Forecast
Next quarter’s earnings estimate for GE9 is EUR 2.02 with a range of EUR 0.61 to EUR 3.40. The previous quarter’s EPS was EUR 4.93. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
HighEUR 1.16B
ConsensusEUR 1.12B
LowEUR 1.08B
GE9 Sales Forecast
Next quarter’s sales forecast for GE9 is EUR 1.12B with a range of EUR 1.08B to EUR 1.16B. The previous quarter’s sales results were EUR 1.03B. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
GE9 Stock Forecast FAQ
What is DE:GE9’s average 12-month price target, according to analysts?
Based on analyst ratings, Genmab A/S’s 12-month average price target is €502.76.
What is DE:GE9’s upside potential, based on the analysts’ average price target?
Genmab A/S has 4.89% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Genmab A/S a Buy, Sell or Hold?
Genmab A/S has a consensus rating of Strong Buy, which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.
What is Genmab A/S’s share price target?
The average share price target for Genmab A/S is €502.76. This is based on 6 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €601.97, and the lowest forecast is €334.43. The average share price target represents a 4.89% increase from the current price of €479.3.
What do analysts say about Genmab A/S?
Genmab A/S’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Street analysts.
How can I buy shares of Genmab A/S?
To buy shares of DE:GE9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
